Axicabtagene Ciloleucel

證據等級: L5

預測適應症: 10 個

Axicabtagene Ciloleucel: From Large B-cell Lymphoma to Crohn’s Colitis

One-Sentence Summary

Axicabtagene ciloleucel (Axi-cel; brand name Yescarta) is a CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy originally developed for relapsed or refractory large B-cell lymphoma and follicular lymphoma. The TxGNN model predicts it may be effective for Crohn’s Colitis, with a prediction score of 91.39%; however, no clinical trials and no publications currently support this specific repurposing direction, and the mechanistic rationale is notably weak.

Quick Overview

Item	Content
Original Indication	Large B-cell Lymphoma / Follicular Lymphoma (per global regulatory approvals; no Canadian authorization on record)
Predicted New Indication	Crohn’s Colitis
TxGNN Prediction Score	91.39%
Evidence Level	L5
Canada Market Status	✗ Not Marketed
Number of DINs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known information, axicabtagene ciloleucel is an autologous CAR-T cell therapy in which the patient’s own T cells are genetically engineered to express a chimeric antigen receptor targeting CD19 — a surface protein expressed on normal and malignant B cells. By redirecting cytotoxic T cells to eliminate CD19-positive cells, Axi-cel achieves deep B-cell depletion in lymphoma patients. Its approved indications are B-cell malignancies, where the target antigen is constitutively expressed on tumor cells.

The proposed extension to Crohn’s colitis rests on a theoretical premise that B-cell elimination might modulate chronic intestinal inflammation. However, the mechanistic link is weak. Crohn’s colitis is predominantly driven by aberrant CD4+ T-cell responses (Th1/Th17 axis) and dysregulated innate immunity at the mucosal barrier — not by B-cell overactivity. Unlike rheumatoid arthritis, where anti-CD20 rituximab has validated B-cell depletion as a meaningful therapeutic strategy, no comparable evidence supports this approach in Crohn’s disease.

An additional safety concern further undermines this prediction: the cytokine release syndrome (CRS) associated with CAR-T infusion could plausibly worsen intestinal inflammation rather than ameliorate it. The high TxGNN score (91.39%) most likely reflects network-level graph topology similarities within the knowledge graph rather than direct biological plausibility. The mechanistic relevance is assessed as weak, and this repurposing direction is not currently supported by available evidence.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

Axicabtagene ciloleucel (Yescarta) is not currently approved or marketed in Canada. No Drug Identification Numbers (DINs) are on record with Health Canada.

For reference: Axi-cel has received marketing authorization in the United States (FDA, October 2017), the European Union (EMA, August 2018), and several other jurisdictions for large B-cell lymphoma and follicular lymphoma. A Canadian Health Canada submission and review would be required before any authorized use in Canada.

Cytotoxicity

Axicabtagene ciloleucel is an antineoplastic cellular immunotherapy. This section applies.

Item	Content
Cytotoxicity Classification	Immunotherapy — CAR-T cell therapy (gene-modified autologous T-cell product); not a conventional cytotoxic agent
Myelosuppression Risk	High — lymphodepletion conditioning (fludarabine + cyclophosphamide) is required prior to infusion; severe and prolonged cytopenias (neutropenia, thrombocytopenia, anemia) are common post-infusion
Emetogenicity Classification	Low from Axi-cel infusion itself; Moderate from the conditioning chemotherapy regimen
Monitoring Items	CBC with differential (daily during hospitalization period), comprehensive metabolic panel, serum ferritin, IL-6 (CRS monitoring), continuous neurological assessment (ICANS grading), vital signs, oxygen saturation
Handling Protection	Requires specialized handling per cellular and gene therapy protocols; must be prepared and administered only at certified treatment centers equipped with tocilizumab, corticosteroids, and intensive care support on standby

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a high TxGNN prediction score of 91.39%, the mechanistic basis for Axi-cel in Crohn’s colitis is weak — Crohn’s disease is a T-cell-predominant disorder where CD19-directed B-cell depletion lacks a clear therapeutic rationale, and the CRS risk profile may actively contraindicate use in an inflamed bowel setting. With zero supporting clinical trials and zero publications (Level L5 — model prediction only), there is insufficient basis to advance this candidate.

To proceed with any further evaluation, the following is needed:

MOA data: Retrieve full mechanism of action and target profile from DrugBank (DB13915) to confirm CD19 specificity and off-target risks
Health Canada product monograph: Obtain the Canadian package insert equivalent for complete safety, contraindication, and DDI profiling
Disease biology review: Commission a literature review on B-cell involvement in specific Crohn’s colitis endotypes (e.g., antibody-positive subgroups) to reassess mechanistic plausibility
CRS risk assessment in IBD: Evaluate whether intestinal inflammation constitutes a contraindication to CAR-T infusion in this patient population
Re-prioritize candidates: Consider advancing the three indications flagged as “Research Question” — rheumatoid vasculitis (moderate mechanistic link via B-cell axis, supported by indirect Schett et al. 2023–2024 autoimmune CAR-T data), idiopathic aplastic anemia (emerging class-effect signal), and ankylosing spondylitis (emerging autoimmune CAR-T field) — before investing further in Crohn’s colitis
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.